Your browser doesn't support javascript.
loading
Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia.
Martín-Izquierdo, Marta; Abáigar, María; Hernández-Sánchez, Jesús M; Tamborero, David; López-Cadenas, Félix; Ramos, Fernando; Lumbreras, Eva; Madinaveitia-Ochoa, Andrés; Megido, Marta; Labrador, Jorge; Sánchez-Real, Javier; Olivier, Carmen; Dávila, Julio; Aguilar, Carlos; Rodríguez, Juan N; Martín-Nuñez, Guillermo; Santos-Mínguez, Sandra; Miguel-García, Cristina; Benito, Rocío; Díez-Campelo, María; Hernández-Rivas, Jesús M.
Afiliação
  • Martín-Izquierdo M; Institute of Biomedical Research of Salamanca, Cancer Research Center-University of Salamanca, Spain.
  • Abáigar M; Institute of Biomedical Research of Salamanca, Cancer Research Center-University of Salamanca, Spain.
  • Hernández-Sánchez JM; Institute of Biomedical Research of Salamanca, Cancer Research Center-University of Salamanca, Spain.
  • Tamborero D; Hospital del Mar Medical Research Institute (IMIM), Barcelona and Karolinska Institutet, Stockholm.
  • López-Cadenas F; University of Salamanca, IBSAL, Hematology, Hospital Clinico Universitario, Salamanca, Spain.
  • Ramos F; Hematology, Hospital Universitario de León, Institute of Biomedicine (IBIOMED), Spain.
  • Lumbreras E; Institute of Biomedical Research of Salamanca, Cancer Research Center-University of Salamanca, Spain.
  • Madinaveitia-Ochoa A; Hematology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Megido M; Hematology, Hospital del Bierzo, Ponferrada, León, Spain.
  • Labrador J; Hematology, Hospital Universitario de Burgos, Burgos, Spain.
  • Sánchez-Real J; Hematology, Hospital Universitario de León, Institute of Biomedicine (IBIOMED), Spain.
  • Olivier C; Hematology, Hospital General de Segovia, Segovia, Spain.
  • Dávila J; Hematology, Hospital Nuestra Señora de Sónsoles, Ávila, Spain.
  • Aguilar C; Hematology, Hospital Santa Bárbara, Soria, Spain.
  • Rodríguez JN; Hematology, Hospital Juan Ramón Jiménez, Huelva, Spain.
  • Martín-Nuñez G; Hematology, Hospital Virgen del Puerto, Plasencia, Spain.
  • Santos-Mínguez S; Institute of Biomedical Research of Salamanca, Cancer Research Center-University of Salamanca, Spain.
  • Miguel-García C; Institute of Biomedical Research of Salamanca, Cancer Research Center-University of Salamanca, Spain.
  • Benito R; Institute of Biomedical Research of Salamanca, Cancer Research Center-University of Salamanca, Spain.
  • Díez-Campelo M; University of Salamanca, IBSAL, Hematology, Hospital Clínico Universitario, Salamanca, Spain.
  • Hernández-Rivas JM; Institute of Biomedical Research of Salamanca, Cancer Research Center-University of Salamanca, Spain.
Haematologica ; 106(8): 2215-2223, 2021 08 01.
Article em En | MEDLINE | ID: mdl-32675227
ABSTRACT
Myelodysplastic syndromes (MDS) are hematological disorders at high risk of progression to secondary acute myeloid leukemia (sAML). However, the mutational dynamics and clonal evolution underlying disease progression are poorly understood at present. To elucidate the mutational dynamics of pathways and genes occurring during the evolution to sAML, next generation sequencing was performed on 84 serially paired samples of MDS patients who developed sAML (discovery cohort) and 14 paired samples from MDS patients who did not progress to sAML during follow-up (control cohort). Results were validated in an independent series of 388 MDS patients (validation cohort). We used an integrative analysis to identify how mutations, alone or in combination, contribute to leukemic transformation. The study showed that MDS progression to sAML is characterized by greater genomic instability and the presence of several types of mutational dynamics, highlighting increasing (STAG2) and newly-acquired (NRAS and FLT3) mutations. Moreover, we observed cooperation between genes involved in the cohesin and Ras pathways in 15-20% of MDS patients who evolved to sAML, as well as a high proportion of newly acquired or increasing mutations in the chromatin-modifier genes in MDS patients receiving a disease-modifying therapy before their progression to sAML.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mieloide Aguda / Segunda Neoplasia Primária Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mieloide Aguda / Segunda Neoplasia Primária Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article